FORT LAUDERDALE, FL—Mr. Cannabis Law’s team, led by Partner Amanda Barton, Esq., served as lead counsel on all legal aspects relating to KetaMD, Inc. – a telehealth company focused on expanding access to ketamine through safe, effective, and affordable at-home treatments. The law firm assisted with the launch of KetaMD, operational compliance for KetaMD, seed round financing of KetaMD, and the acquisition of KetaMD by Braxia Scientific Corp.– a leader in the treatment and research of mental health conditions through ketamine and psychedelic medicine.
The acquisition of KetaMD by Braxia Scientific Corp created one of the most robust networks of physical ketamine clinics and virtual ketamine telehealth services. KetaMD recently launched operations in Florida, with the intention and infrastructure to expand across the nation in the coming months. Through its secure, HIPAA-compliant telemedicine platform, KetaMD hopes to revolutionize the treatment of those who are suffering from depression, anxiety, and other mental health challenges.
In June 2020, KetaMD hired Mr. Cannabis Law to help with all legal aspects related to launching one of the first ketamine telehealth companies, including corporate structuring, operational compliance, telehealth compliance, HIPPA compliance, seed round financing, and various other legal matters.
As an early mover in the industry with strong technology, KetaMD quickly attracted several publicly-traded companies interested in acquiring KetaMD. To determine the best partner, KetaMD and Mr. Cannabis Law performed significant diligence on many of these publicly-traded companies. Ultimately, KetaMD determined that Braxia was the best fit to scale the KetaMD business and to become one of the leading ketamine providers in the world. Barton of Mr. Cannabis Law was able to lead a team of attorneys to help guide KetaMD through the entire acquisition process. The transaction closed on August 2, 2022.
